Story

Capricor Therapeutics Stock Rallies as FDA Extends Review for DMD Drug

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20262 min read
Capricor Therapeutics Stock Rallies as FDA Extends Review for DMD Drug
Text size
Background

Shares of Capricor Therapeutics (NASDAQ: CAPR) rose sharply in pre-market trading after the U.S. Food and Drug Administration (FDA) extended its review period for the company's Duchenne muscular dystrophy (DMD) treatment, deramiocel. The decision pushes the target action date back by three months, a development that investors are viewing as constructive for the drug's approval pathway.

FDA Extends Review, Avoiding Rejection

The FDA has set a new Prescription Drug User Fee Act (PDUFA) target action date of November 22, 2026, delayed from the original date of August 22, 2026. The extension was prompted by Capricor's submission of an amendment to its Biologics License Application (BLA), which included new 24-month data from its pivotal Phase 3 HOPE-3 study.

Critically for investors, the agency did not issue a Complete Response Letter (CRL), which would have effectively rejected the application and likely required new clinical trials. The FDA's willingness to take additional time to review the new long-term data is being interpreted as a sign that the application remains under active and serious consideration.

Market and Analyst Reaction

The market reacted positively to the news, with Capricor's stock climbing 6.9% in pre-open trading and extending a rally from the prior session. The move signals investor relief that the company avoided the significant setback of a CRL.

Sample IUX Markets – In-articleAd

Analyst sentiment has also grown more positive, underpinning the rally. Following the news, Oppenheimer upgraded CAPR shares to Outperform from Perform. This follows a recent upgrade from Cantor Fitzgerald, which raised its rating to Overweight and increased its price target to $28 from $3.50.

Context and Outlook

Deramiocel is an investigational cell therapy for the treatment of Duchenne muscular dystrophy, a rare genetic disorder causing progressive muscle weakness. The amended application includes analyses supporting a refined indication focused on upper limb function, which was the primary endpoint of the HOPE-3 trial.

The stock's volatile 52-week range of $2.96 to $40.37 underscores the high-risk, high-reward nature of clinical-stage biotechnology companies awaiting pivotal regulatory decisions. The rally was highly company-specific, significantly outpacing modest gains in the broader market indices.

Read next

More on Stocks
Back to latest news

LATEST